Additionally, patients receiving IL-23 inhibitors exhibited greater angioma counts compared to those on TNF-α inhibitors, indicating a potential pro-angiogenic effect of IL-23 blockade, possibly mediated through VEGF modulation. This evidence concerns the gene IL37 and hemangioma.